- Home
- RIGL vs GPRK Comparison
RIGL vs GPRK Comparison
Compare RIGL & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- GPRK
- Stock Information
- Founded
- RIGL 1996
- GPRK 2002
- Country
- RIGL United States
- GPRK Colombia
- Employees
- RIGL N/A
- GPRK N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- GPRK Oil & Gas Production
- Sector
- RIGL Health Care
- GPRK Energy
- Exchange
- RIGL Nasdaq
- GPRK Nasdaq
- Market Cap
- RIGL 335.5M
- GPRK 335.7M
- IPO Year
- RIGL 2000
- GPRK N/A
- Fundamental
- Price
- RIGL $38.85
- GPRK $6.60
- Analyst Decision
- RIGL Buy
- GPRK Buy
- Analyst Count
- RIGL 5
- GPRK 1
- Target Price
- RIGL $38.20
- GPRK $11.00
- AVG Volume (30 Days)
- RIGL 995.6K
- GPRK 689.9K
- Earning Date
- RIGL 08-05-2025
- GPRK 08-05-2025
- Dividend Yield
- RIGL N/A
- GPRK 8.91%
- EPS Growth
- RIGL N/A
- GPRK N/A
- EPS
- RIGL 5.43
- GPRK 0.81
- Revenue
- RIGL $267,921,000.00
- GPRK $560,354,000.00
- Revenue This Year
- RIGL $59.93
- GPRK N/A
- Revenue Next Year
- RIGL N/A
- GPRK N/A
- P/E Ratio
- RIGL $7.15
- GPRK $8.19
- Revenue Growth
- RIGL 105.62
- GPRK N/A
- 52 Week Low
- RIGL $12.66
- GPRK $5.66
- 52 Week High
- RIGL $43.72
- GPRK $11.72
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- GPRK 50.84
- Support Level
- RIGL $39.00
- GPRK $6.28
- Resistance Level
- RIGL $42.08
- GPRK $6.67
- Average True Range (ATR)
- RIGL 2.32
- GPRK 0.20
- MACD
- RIGL -0.37
- GPRK 0.02
- Stochastic Oscillator
- RIGL 53.26
- GPRK 63.01
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.